Patent ID: 8247419

Claim:
A method of treating an individual suffering from a mutant KIT kinase disorder comprising administering to the individual a therapeutically effective amount of ′N-(2-chloro-6-methylphenyl)-2-[[6-[4- (2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, or a pharmaceutically acceptable salt or hydrate thereof, and a therapeutically effective amount of rapamycin, wherein administration of the ′N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, or a pharmaceutically acceptable salt or hydrate thereof in combination with rapamycin results in synergistic inhibition of the mutant KIT kinase, wherein the mutant KIT kinase disorder is selected from the group consisting of mast cell disease, gastrointestinal stromal tumors, leukemia, and testicular seminorna, wherein said mutant KIT kinase comprises a mutation at amino acid residue 816 of KIT kinase (SEQ ID NO:2).